Authors:
Martinetti, A
Ferrari, L
Celio, L
Mariani, L
Miceli, R
Zilembo, N
Di Bartolomeo, M
Toffolatti, L
Pozzi, P
Seregni, E
Bombardieri, E
Bajetta, E
Citation: A. Martinetti et al., The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers, J STEROID B, 75(1), 2000, pp. 65-73
Authors:
Bajetta, E
Zilembo, N
Bichisao, E
Martinetti, A
Buzzoni, R
Pozzi, P
Bidoli, P
Ferrari, L
Celio, L
Citation: E. Bajetta et al., Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors, ANN ONCOL, 11(8), 2000, pp. 1017-1022
Authors:
Lonning, PE
Bajetta, E
Murray, R
Tubiana-Hulin, M
Eisenberg, PD
Mickiewicz, E
Celio, L
Pitt, P
Mita, M
Aaronson, NK
Fowst, C
Arkhipov, A
di Salle, E
Polli, A
Massimini, G
Citation: Pe. Lonning et al., Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial, J CL ONCOL, 18(11), 2000, pp. 2234-2244
Authors:
Salvadori, B
Celio, L
Oriana, R
Bajetta, E
Citation: B. Salvadori et al., Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer: Long-term results of an experience at the Milan Cancer Institute, TUMORI, 86(3), 2000, pp. 258-259
Authors:
Bajetta, E
Zilembo, N
Dowsett, M
Guillevin, L
Di Leo, A
Celio, L
Martinetti, A
Marchiano, A
Pozzi, P
Stani, S
Bichisao, E
Citation: E. Bajetta et al., Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients, EUR J CANC, 35(2), 1999, pp. 208-213
Authors:
Del Vecchio, M
Procopio, G
Cassata, A
Pozzi, P
Busto, G
Celio, L
Bajetta, E
Citation: M. Del Vecchio et al., Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT, TUMORI, 85(1), 1999, pp. 6-11
Authors:
Celio, L
Martinetti, A
Ferrari, L
Buzzoni, R
Mariani, L
Miceli, R
Seregni, E
Procopio, G
Cassata, A
Bombardieri, E
Bajetta, E
Citation: L. Celio et al., Premenopausal breast cancer patients treated with a gonadotropin-releasinghormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study, ANTICANC R, 19(3B), 1999, pp. 2261-2268
Authors:
Bajetta, E
Ferrari, L
Martinetti, A
Celio, L
Procopio, G
Artale, S
Zilembo, N
Di Bartolomeo, M
Seregni, E
Bombardieri, E
Citation: E. Bajetta et al., Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors, CANCER, 86(5), 1999, pp. 858-865